Last: | $10.61 |
---|---|
Change Percent: | 0.29% |
Open: | $10.46 |
Close: | $10.61 |
High: | $10.8 |
Low: | $10.45 |
Volume: | 3,778,834 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$10.61 | $10.46 | $10.61 | $10.8 | $10.45 | 3,778,834 | 03-28-2024 |
$10.49 | $9.9 | $10.49 | $10.49 | $9.88 | 6,336,459 | 03-27-2024 |
$9.86 | $9.49 | $9.86 | $9.93 | $9.47 | 3,089,355 | 03-26-2024 |
$9.48 | $9.64 | $9.48 | $9.89 | $9.47 | 2,192,227 | 03-25-2024 |
$9.56 | $9.43 | $9.56 | $9.575 | $9.385 | 1,138,699 | 03-22-2024 |
$9.5 | $9.54 | $9.5 | $9.625 | $9.43 | 1,684,267 | 03-21-2024 |
$9.59 | $9.51 | $9.59 | $9.62 | $9.345 | 1,430,423 | 03-20-2024 |
$9.54 | $9.33 | $9.54 | $9.57 | $9.28 | 1,465,120 | 03-19-2024 |
$9.38 | $9.29 | $9.38 | $9.385 | $9.16 | 1,195,972 | 03-18-2024 |
$9.2 | $9.15 | $9.2 | $9.24 | $9.07 | 1,385,517 | 03-15-2024 |
$9.09 | $9.2 | $9.09 | $9.27 | $9.035 | 1,037,885 | 03-14-2024 |
$9.28 | $9.23 | $9.28 | $9.425 | $9.21 | 1,075,220 | 03-13-2024 |
$9.19 | $9.14 | $9.19 | $9.205 | $9.07 | 1,027,329 | 03-12-2024 |
$9.12 | $9.21 | $9.12 | $9.265 | $9.1027 | 1,121,071 | 03-11-2024 |
$9.23 | $9.35 | $9.23 | $9.41 | $9.15 | 1,200,279 | 03-08-2024 |
$9.28 | $9.27 | $9.28 | $9.34 | $9.125 | 1,381,620 | 03-07-2024 |
$9.23 | $9.62 | $9.23 | $9.68 | $9.18 | 2,660,969 | 03-06-2024 |
$9.56 | $9.55 | $9.56 | $9.635 | $9.36 | 2,467,862 | 03-05-2024 |
$9.58 | $9.79 | $9.58 | $9.88 | $9.48 | 2,860,876 | 03-04-2024 |
$9.89 | $9.47 | $9.89 | $9.9 | $9.285 | 5,991,150 | 03-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Bausch Health Companies Inc. Company Name:
BHC Stock Symbol:
NYSE Market:
2024-03-21 00:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
LAVAL, QC / ACCESSWIRE / March 6, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced that it is supporting a Phase 2 investigator-initiated study (IIS) of RELISTOR® (methylnaltrexone bromide: MNTX) in patients wi...
Salix Pharmaceuticals Releases Findings from First Colonoscopy Awareness Survey LAVAL, QC / ACCESSWIRE / March 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced findings from its first colonoscopy awareness an...